Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Emerging roles of F-box proteins in cancer drug resistance.

Yan L, Lin M, Pan S, Assaraf YG, Wang ZW, Zhu X.

Drug Resist Updat. 2019 Dec 17;49:100673. doi: 10.1016/j.drup.2019.100673. [Epub ahead of print] Review.

PMID:
31877405
2.

Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets.

Kopecka J, Trouillas P, Gašparović AČ, Gazzano E, Assaraf YG, Riganti C.

Drug Resist Updat. 2019 Nov 29;49:100670. doi: 10.1016/j.drup.2019.100670. [Epub ahead of print] Review.

PMID:
31846838
3.

Towards the overcoming of anticancer drug resistance mediated by p53 mutations.

Cao X, Hou J, An Q, Assaraf YG, Wang X.

Drug Resist Updat. 2019 Nov 30;49:100671. doi: 10.1016/j.drup.2019.100671. [Epub ahead of print] Review.

PMID:
31841768
4.

Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance.

Narayanan S, Cai CY, Assaraf YG, Guo HQ, Cui Q, Wei L, Huang JJ, Ashby CR Jr, Chen ZS.

Drug Resist Updat. 2020 Jan;48:100663. doi: 10.1016/j.drup.2019.100663. Epub 2019 Nov 11. Review.

PMID:
31785545
5.

Alterations in ZnT1 expression and function lead to impaired intracellular zinc homeostasis in cancer.

Lehvy AI, Horev G, Golan Y, Glaser F, Shammai Y, Assaraf YG.

Cell Death Discov. 2019 Nov 12;5:144. doi: 10.1038/s41420-019-0224-0. eCollection 2019.

6.

Advanced technological tools to study multidrug resistance in cancer.

Andrei L, Kasas S, Ochoa Garrido I, Stanković T, Suárez Korsnes M, Vaclavikova R, Assaraf YG, Pešić M.

Drug Resist Updat. 2020 Jan;48:100658. doi: 10.1016/j.drup.2019.100658. Epub 2019 Oct 17. Review.

PMID:
31678863
7.

The multi-factorial nature of clinical multidrug resistance in cancer.

Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPR, Vasconcelos MH.

Drug Resist Updat. 2019 Sep;46:100645. doi: 10.1016/j.drup.2019.100645. Epub 2019 Sep 17.

PMID:
31585396
8.

Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.

Leonetti A, Wever B, Mazzaschi G, Assaraf YG, Rolfo C, Quaini F, Tiseo M, Giovannetti E.

Drug Resist Updat. 2019 Sep;46:100644. doi: 10.1016/j.drup.2019.100644. Epub 2019 Sep 17.

PMID:
31585395
9.

Selective eradication of human non-small cell lung cancer cells using aptamer-decorated nanoparticles harboring a cytotoxic drug cargo.

Engelberg S, Netzer E, Assaraf YG, Livney YD.

Cell Death Dis. 2019 Sep 20;10(10):702. doi: 10.1038/s41419-019-1870-0.

10.

Metabolomics reveals novel insight on dormancy of aquatic invertebrate encysted embryos.

Rozema E, Kierszniowska S, Almog-Gabai O, Wilson EG, Choi YH, Verpoorte R, Hamo R, Chalifa-Caspi V, Assaraf YG, Lubzens E.

Sci Rep. 2019 Jun 20;9(1):8878. doi: 10.1038/s41598-019-45061-x.

11.

Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.

Levin M, Stark M, Berman B, Assaraf YG.

Cell Death Dis. 2019 May 17;10(6):390. doi: 10.1038/s41419-019-1626-x.

12.

Developing Body-Components-Based Theranostic Nanoparticles for Targeting Ovarian Cancer.

Edelman R, Assaraf YG, Slavkin A, Dolev T, Shahar T, Livney YD.

Pharmaceutics. 2019 May 5;11(5). pii: E216. doi: 10.3390/pharmaceutics11050216.

13.

Correction: Demonstrating aspects of multiscale modeling by studying the permeation pathway of the human ZnT2 zinc transporter.

Golan Y, Alhadeff R, Glaser F, Ganoth A, Warshel A, Assaraf YG.

PLoS Comput Biol. 2019 May 1;15(5):e1007021. doi: 10.1371/journal.pcbi.1007021. eCollection 2019 May.

14.

ZnT2 is an electroneutral proton-coupled vesicular antiporter displaying an apparent stoichiometry of two protons per zinc ion.

Golan Y, Alhadeff R, Warshel A, Assaraf YG.

PLoS Comput Biol. 2019 Mar 20;15(3):e1006882. doi: 10.1371/journal.pcbi.1006882. eCollection 2019 Mar.

15.

Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity.

Zhitomirsky B, Yunaev A, Kreiserman R, Kaplan A, Stark M, Assaraf YG.

Cell Death Dis. 2018 Dec 13;9(12):1191. doi: 10.1038/s41419-018-1227-0.

16.

MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.

Leonetti A, Assaraf YG, Veltsista PD, El Hassouni B, Tiseo M, Giovannetti E.

Drug Resist Updat. 2019 Jan;42:1-11. doi: 10.1016/j.drup.2018.11.002. Epub 2018 Nov 28. Review.

PMID:
30544036
17.

Modulating ROS to overcome multidrug resistance in cancer.

Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta P, Wei L, Ashby CR Jr, Yang DH, Chen ZS.

Drug Resist Updat. 2018 Nov;41:1-25. doi: 10.1016/j.drup.2018.11.001. Epub 2018 Nov 14. Review.

PMID:
30471641
18.

High proportion of transient neonatal zinc deficiency causing alleles in the general population.

Golan Y, Lehvy A, Horev G, Assaraf YG.

J Cell Mol Med. 2019 Feb;23(2):828-840. doi: 10.1111/jcmm.13982. Epub 2018 Nov 18.

19.

Demonstrating aspects of multiscale modeling by studying the permeation pathway of the human ZnT2 zinc transporter.

Golan Y, Alhadeff R, Glaser F, Ganoth A, Warshel A, Assaraf YG.

PLoS Comput Biol. 2018 Nov 2;14(11):e1006503. doi: 10.1371/journal.pcbi.1006503. eCollection 2018 Nov. Erratum in: PLoS Comput Biol. 2019 May 1;15(5):e1007021.

20.

β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer.

Bar-Zeev M, Kelmansky D, Assaraf YG, Livney YD.

Eur J Pharm Biopharm. 2018 Dec;133:240-249. doi: 10.1016/j.ejpb.2018.10.018. Epub 2018 Oct 24.

PMID:
30367935
21.

Cancer cell-selective, clathrin-mediated endocytosis of aptamer decorated nanoparticles.

Engelberg S, Modrejewski J, Walter JG, Livney YD, Assaraf YG.

Oncotarget. 2018 Apr 20;9(30):20993-21006. doi: 10.18632/oncotarget.24772. eCollection 2018 Apr 20.

22.

The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity.

Levin M, Stark M, Assaraf YG.

Oncotarget. 2018 Mar 30;9(24):16861-16882. doi: 10.18632/oncotarget.24717. eCollection 2018 Mar 30.

23.

Redundant angiogenic signaling and tumor drug resistance.

Gacche RN, Assaraf YG.

Drug Resist Updat. 2018 Jan;36:47-76. doi: 10.1016/j.drup.2018.01.002. Epub 2018 Jan 17. Review.

PMID:
29499837
24.

Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.

Oerlemans R, Berkers CR, Assaraf YG, Scheffer GL, Peters GJ, Verbrugge SE, Cloos J, Slootstra J, Meloen RH, Shoemaker RH, Dijkmans BAC, Scheper RJ, Ovaa H, Jansen G.

Invest New Drugs. 2018 Oct;36(5):797-809. doi: 10.1007/s10637-018-0569-x. Epub 2018 Feb 14.

25.

LysoTracker and MitoTracker Red are transport substrates of P-glycoprotein: implications for anticancer drug design evading multidrug resistance.

Zhitomirsky B, Farber H, Assaraf YG.

J Cell Mol Med. 2018 Apr;22(4):2131-2141. doi: 10.1111/jcmm.13485. Epub 2018 Jan 26.

26.

Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.

Genovese I, Ilari A, Assaraf YG, Fazi F, Colotti G.

Drug Resist Updat. 2017 May;32:23-46. doi: 10.1016/j.drup.2017.10.003. Epub 2017 Oct 16. Review.

27.

Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.

Giovannetti E, Zucali PA, Assaraf YG, Funel N, Gemelli M, Stark M, Thunnissen E, Hou Z, Muller IB, Struys EA, Perrino M, Jansen G, Matherly LH, Peters GJ.

Ann Oncol. 2017 Nov 1;28(11):2725-2732. doi: 10.1093/annonc/mdx499.

28.

A mechanopharmacology approach to overcome chemoresistance in pancreatic cancer.

Coppola S, Carnevale I, Danen EHJ, Peters GJ, Schmidt T, Assaraf YG, Giovannetti E.

Drug Resist Updat. 2017 Mar;31:43-51. doi: 10.1016/j.drup.2017.07.001. Epub 2017 Jul 24. Review.

PMID:
28867243
29.

Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.

Bar-Zeev M, Livney YD, Assaraf YG.

Drug Resist Updat. 2017 Mar;31:15-30. doi: 10.1016/j.drup.2017.05.002. Epub 2017 May 21. Review.

PMID:
28867241
30.

The role of the zinc transporter SLC30A2/ZnT2 in transient neonatal zinc deficiency.

Golan Y, Kambe T, Assaraf YG.

Metallomics. 2017 Oct 18;9(10):1352-1366. doi: 10.1039/c7mt00162b. Review.

PMID:
28665435
31.

Albumin and Hyaluronic Acid-Coated Superparamagnetic Iron Oxide Nanoparticles Loaded with Paclitaxel for Biomedical Applications.

Vismara E, Bongio C, Coletti A, Edelman R, Serafini A, Mauri M, Simonutti R, Bertini S, Urso E, Assaraf YG, Livney YD.

Molecules. 2017 Jun 22;22(7). pii: E1030. doi: 10.3390/molecules22071030.

32.

Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.

Stark M, Assaraf YG.

Oncotarget. 2017 Jul 25;8(30):49973-49987. doi: 10.18632/oncotarget.18385.

33.

The importance of breast cancer resistance protein to the kidneys excretory function and chemotherapeutic resistance.

Caetano-Pinto P, Jansen J, Assaraf YG, Masereeuw R.

Drug Resist Updat. 2017 Jan;30:15-27. doi: 10.1016/j.drup.2017.01.002. Epub 2017 Jan 11. Review.

PMID:
28363332
34.

Hyaluronic acid-serum albumin conjugate-based nanoparticles for targeted cancer therapy.

Edelman R, Assaraf YG, Levitzky I, Shahar T, Livney YD.

Oncotarget. 2017 Apr 11;8(15):24337-24353. doi: 10.18632/oncotarget.15363.

35.

Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis.

Zhitomirsky B, Assaraf YG.

Oncotarget. 2017 Jul 11;8(28):45117-45132. doi: 10.18632/oncotarget.15155.

36.

Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.

Wijdeven RH, Pang B, Assaraf YG, Neefjes J.

Drug Resist Updat. 2016 Sep;28:65-81. doi: 10.1016/j.drup.2016.07.001. Epub 2016 Jul 16. Review.

PMID:
27620955
37.

Folylpoly-γ-glutamate synthetase: A key determinant of folate homeostasis and antifolate resistance in cancer.

Raz S, Stark M, Assaraf YG.

Drug Resist Updat. 2016 Sep;28:43-64. doi: 10.1016/j.drup.2016.06.004. Epub 2016 Jul 4. Review.

PMID:
27620954
38.

Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.

Franke NE, Kaspers GL, Assaraf YG, van Meerloo J, Niewerth D, Kessler FL, Poddighe PJ, Kole J, Smeets SJ, Ylstra B, Bi C, Chng WJ, Horton TM, Menezes RX, Musters RJ, Zweegman S, Jansen G, Cloos J.

Oncotarget. 2016 Nov 15;7(46):74779-74796. doi: 10.18632/oncotarget.11340.

39.

Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.

Li W, Zhang H, Assaraf YG, Zhao K, Xu X, Xie J, Yang DH, Chen ZS.

Drug Resist Updat. 2016 Jul;27:14-29. doi: 10.1016/j.drup.2016.05.001. Epub 2016 May 13. Review.

PMID:
27449595
40.

Repositioning of drugs for intervention in tumor progression and metastasis: Old drugs for new targets.

Mudduluru G, Walther W, Kobelt D, Dahlmann M, Treese C, Assaraf YG, Stein U.

Drug Resist Updat. 2016 May;26:10-27. doi: 10.1016/j.drup.2016.03.002. Epub 2016 Mar 24. Review.

PMID:
27180307
41.

Could drugs inhibiting the mevalonate pathway also target cancer stem cells?

Likus W, Siemianowicz K, Bieńk K, Pakuła M, Pathak H, Dutta C, Wang Q, Shojaei S, Assaraf YG, Ghavami S, Cieślar-Pobuda A, Łos MJ.

Drug Resist Updat. 2016 Mar;25:13-25. doi: 10.1016/j.drup.2016.02.001. Epub 2016 Feb 20. Review.

42.

Molecular Basis of Transient Neonatal Zinc Deficiency: NOVEL ZnT2 MUTATIONS DISRUPTING ZINC BINDING AND PERMEATION.

Golan Y, Itsumura N, Glaser F, Berman B, Kambe T, Assaraf YG.

J Biol Chem. 2016 Jun 24;291(26):13546-59. doi: 10.1074/jbc.M116.732693. Epub 2016 May 2.

43.

The association of aberrant folylpolyglutamate synthetase splicing with ex vivo methotrexate resistance and clinical outcome in childhood acute lymphoblastic leukemia.

Wojtuszkiewicz A, Assaraf YG, Hoekstra M, Sciarrillo R, Jansen G, Peters GJ, Pieters R, Sonneveld E, Escherich G, Kaspers GJ, Cloos J.

Haematologica. 2016 Jul;101(7):e291-4. doi: 10.3324/haematol.2016.142794. Epub 2016 Apr 1. No abstract available.

44.
45.

Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation.

Ferreira JA, Peixoto A, Neves M, Gaiteiro C, Reis CA, Assaraf YG, Santos LL.

Drug Resist Updat. 2016 Jan;24:34-54. doi: 10.1016/j.drup.2015.11.003. Epub 2015 Nov 25. Review.

PMID:
26830314
46.

Lysosomes as mediators of drug resistance in cancer.

Zhitomirsky B, Assaraf YG.

Drug Resist Updat. 2016 Jan;24:23-33. doi: 10.1016/j.drup.2015.11.004. Epub 2015 Nov 26. Review.

PMID:
26830313
47.

Exosomes Secreted by Apoptosis-Resistant Acute Myeloid Leukemia (AML) Blasts Harbor Regulatory Network Proteins Potentially Involved in Antagonism of Apoptosis.

Wojtuszkiewicz A, Schuurhuis GJ, Kessler FL, Piersma SR, Knol JC, Pham TV, Jansen G, Musters RJ, van Meerloo J, Assaraf YG, Kaspers GJ, Zweegman S, Cloos J, Jimenez CR.

Mol Cell Proteomics. 2016 Apr;15(4):1281-98. doi: 10.1074/mcp.M115.052944. Epub 2016 Jan 22.

48.

Prognostic and Predictive Roles of Thymidylate Synthase Expression in Lung Cancer: The Debate Is Still Open.

Giovannetti E, Zucali PA, Rolfo C, Assaraf YG, Peters GJ.

J Clin Oncol. 2016 Feb 10;34(5):511-2. doi: 10.1200/JCO.2015.64.2496. Epub 2015 Dec 28. No abstract available.

PMID:
26712221
49.

Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.

Taddia L, D'Arca D, Ferrari S, Marraccini C, Severi L, Ponterini G, Assaraf YG, Marverti G, Costi MP.

Drug Resist Updat. 2015 Nov;23:20-54. doi: 10.1016/j.drup.2015.10.003. Epub 2015 Oct 31. Review.

PMID:
26690339
50.

Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance.

Wojtuszkiewicz A, Raz S, Stark M, Assaraf YG, Jansen G, Peters GJ, Sonneveld E, Kaspers GJ, Cloos J.

Int J Cancer. 2016 Apr 1;138(7):1645-56. doi: 10.1002/ijc.29919. Epub 2015 Nov 25.

Supplemental Content

Loading ...
Support Center